Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA extends DTC guidance comment period

Executive Summary

FDA reopens comment period for draft guidances on direct-to-consumer advertising until Aug. 10. "We got comments that folks wanted more time to do DTC research, complete DTC research and also more time to provide comments," Ad Division Director Tom Abrams said during a DIA audioconference May 27. The agency also plans to conduct its own research on the content and format of the brief summary. FDA released the DTC guidances Feb. 4 (1"The Pink Sheet" Feb. 9, 2004, p. 3)...

You may also be interested in...

FDA Releases DTC Guidances; “Not The Last Word” On Ads, McClellan Says

FDA's publication of three draft guidances on direct-to-consumer advertising is unlikely to relieve pressure on the agency to explain its approach to enforcement actions against drug manufacturers that repeatedly run false and misleading promotions

Sanofi Alliance Is Big Boost For Company Behind Type 1 Diabetes Prevention Drug

Sanofi has deprioritized its presence in type 1 diabetes in recent years but could help turn teplizumab into a game-changer blockbuster product.

Biogen’s RoActemra Biosimilar Begins EU Approvals Process

The European Medicines Agency has accepted Biogen’s marketing authorization submission for its BIIB800, developed by Chinese firm Bio-Thera.

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts